)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Boundless Bio (BOLD) investor relations material
Boundless Bio Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary5 Aug, 2025
Executive summary
Focused on precision oncology targeting oncogene amplified tumors using ecDNA-directed therapeutics (ecDTx) and advancing BBI-355/BBI-825 and BBI-940 programs.
Portfolio reprioritization in Q2 2025: discontinued certain clinical trial arms, advanced BBI-355/BBI-825 combination, and selected BBI-940 as a new development candidate.
Workforce reduced by one-third in Q2 2025 to streamline operations and extend cash runway.
No products approved or revenue generated to date; expects continued losses as development progresses.
Cash position of $127 million supports operations into the first half of 2028, covering expected proof-of-concept clinical readouts.
Financial highlights
Net loss of $15.7 million for Q2 2025, compared to $17.0 million in Q2 2024; net loss per share was $0.70 for Q2 2025, compared to $0.77 for Q2 2024.
R&D expenses decreased to $12.2 million in Q2 2025 from $14.7 million in Q2 2024.
G&A expenses rose to $4.8 million in Q2 2025 from $4.6 million in Q2 2024.
Cash, cash equivalents, and short-term investments totaled $127.1 million as of June 30, 2025.
Net cash used in operating activities was $26.4 million for the first half of 2025, down from $32.0 million year-over-year.
Outlook and guidance
Existing cash and investments expected to fund operations into the first half of 2028, based on current plans.
Initial proof-of-concept clinical data for BBI-355/BBI-825 combination and BBI-940 anticipated within current cash runway.
IND submission for BBI-940 anticipated in the first half of 2026.
Substantial additional funding will be required for long-term development and commercialization.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Boundless Bio earnings date
Q3 20256 Nov, 2025
Next Boundless Bio earnings date
Q3 20256 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Boundless Bio Inc., trading under the NASDAQ symbol BOLD, is a clinical-stage oncology company focused on developing novel cancer treatments. The company leverages its proprietary Spyglass platform to target extrachromosomal DNA (ecDNA), which plays a significant role in oncogene amplification in over 14% of cancer patients. By identifying and inhibiting targets essential for ecDNA functionality, Boundless Bio aims to develop ecDNA-directed therapeutic candidates (ecDTx) designed to selectively eliminate cancer cells containing ecDNA without harming healthy cells. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage